Abstract:Multiple myeloma (MM) is a malignancy of post-germinal centre B-cells whose pathogenesis is only partially understood. Chromosomal hyperdiploidy and recurrent immunoglobulin gene locus rearrangements are frequent, but are insufficient for malignant transformation, which is associated with additional events such as somatic mutations, epigenomic aberrations, and chromosomal copy-number changes.To investigate genomic event underlying MM pathogenesis and evolution, we used whole exome sequencing, copy number profiling and cytogenetics in 67 patients and 84 samples. For 15 patients, 2 or 3 serial samples (median 299 days apart) were available. Exome reads were used to call substitutions and indels. We used the Genome-Wide SNP Array 6.0 or exome reads to estimate the allele-specific copy number of the tumor. To cluster variants and estimate the clonal architecture of each sample and its evolution over time, we used the mutation burden, corrected for copy number and normal cell contamination.Analysis of the clonal structure of the tumors showed at least one subclone in 94% of patients at diagnosis, suggesting that myeloma is a heterogeneous disease at presentation. Interestingly, many mutations of known MM driver genes (KRAS, NRAS, BRAF, TP53, FAM46C) were subclonal at diagnosis. In 5/67 patients, BRAF and KRAS/NRAS mutations co-existed in the same sample, raising therapeutic implications given the paradoxical ERK-activating effect of BRAF inhibitors in RAS -mutated cells. Furthermore, only 3/10 BRAF variants were V600E, the current target of most inhibitors.Altogether, only the 5 previously known genes were significantly enriched in our cohort, highlighting marked heterogeneity of the spectrum of candidate driver gene mutations across MM patients. Nevertheless, we identified several new recurrent gene lesions: inactivating mutations of SP140 (7.5%), a gene previously linked to germline susceptibility to CLL, and in ROBO1 (7.5%), a gene recently implicated in pancreatic cancer; clustered missense substitutions in EGR1 (6%) , a gene previously implicated in plasma cell apoptosis; clustered truncating mutations in LTB (4.5%), a TNF-family protein implicated in lymphoid development.The subclonal structure of the sample changed over time in 72% paired samples, highlighting genomic evolution at relapse. We described 4 different scenarios with striking concordance between mutations and chromosomal copy number changes: no change, linear evolution (a new clone appears in the later sample), differential clonal response (the relative proportions of the subclones change over time), and branching evolution (new clones emerge, while others decline in frequency or disappear). All subclonal variants in known driver myeloma genes increased their clonal fraction at the later time-point, consistent with the expected positive selection for the subclones harboring them.To investigate mutational processes responsible for the generation of the mutational repertoire in MM, we extracted the variant context and analyzed the mutational signatures. We found two signatures in our samples. The most represented one is enriched for spontaneous deamination of methylated cytosines, a common process in cancer and aged cells. The second signature was more represented in samples showing extremely high numbers of variants, sometimes clustered in small regions of ∼200 bp (kataegis). We hypothesize that it results from aberrant activity of the APOBEC family of cytosine deaminases, recently described in breast cancer. Interestingly, cases of extramedulary relapse were always associated with branching evolution and showed increased contribution from this APOBEC signature.In conclusion, in our cohort of MM samples we show: 1) evidence of tumor heterogeneity at the time of diagnosis; 2) discernable genetic changes and shifts in the clonal structure of disease at the time of progression; 3) different mutational processes responsible for an heterogeneous mutational repertoire across patients, and over time in the same patient; 4) a comprehensive list of recurrent variants, many of which are previously unreported. Our study provides new insights into the genomic architecture of MM, and will help identify molecular alterations associated with progression of disease and development of drug resistance.Disclosures: Tai: Onyx: Consultancy. Richardson: Millennium: Membership on an entity’s Board of Directors or advisory committees; Johnson & Johnson: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees. Moreau: Celgene: Honoraria, Speakers Bureau. Attal: CELGENE: Honoraria, Speakers Bureau; JANSSEN: Honoraria, Speakers Bureau. Anderson: Celgene, Millennium, BMS, Onyx: Membership on an entity’s Board of Directors or advisory committees; Acetylon, Oncopep: Scientific Founder , Scientific Founder Other.

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma

Insights into the Basis of Chromosomal Imbalances During the Clonal Evolution of Multiple Myeloma Using Snp Array Analysis.

High-Resolution Genomic Profiles Identify Novel Genes And/Or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients

Prognostic Power of Abnormal Cytogenetics for Multiple Myeloma: a Multicenter Study in China.

Retrospective Analysis of Cytogenetic and Clinical Characteristics on 65 Patients with Multiple Myeloma

Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma

A Retrospective Analysis of Cytogenetic and Clinical Characteristics in Patients with Multiple Myeloma

Chromosomal Deletions and Amplifications in Multiple Myeloma Detected by 500k Single Nucleotide Polymorphism Array Analysis.

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response

Prognostic Significance Of Copy-Number Alterations In Multiple Myeloma

Gene Mutations Detected By Whole-Exome Sequencing And Recurrent Cytogenetic Abnormalities Are Independent Events In Multiple Myeloma

Whole Exome Sequencing of Multiple Myeloma Reveals an Heterogeneous Clonal Architecture and Genomic Evolution

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

Evolution of Genomic Changes and Their Significance in Myeloma.

Identification of Collaborating Oncogeneic Events Leading to Disease Progression in Myeloma Cases with A T(4;14) and T(11;14) Using Snp and Gene Expression Arrays.

Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma

Single Cell Whole Genome Measurement of Genomic Heterogeneity and Clonal Evolution in Multiple Myeloma

In Myeloma, the Prognostic Impact of Hyperdiploidy is Mainly Related to the Gain of Chromosome 5

Use Of High-Density Snp-Array Analysis To Identify Novel Chromosomal Abnormalities That Predict Survival In Multiple Myeloma